Market News
Stay updated with the latest market trends, earnings, and economic indicators.
OneSource Specialty Pharma consolidated net profit declines 95.33% in the March 2026 quarter
Sales rise 0.53% to Rs 428.22 crore
OneSource Specialty Pharma shares fall as Q4 profit plunges 95%, margin halves
OneSource Specialty Pharma reports a sharp decline in Q4FY26 profit, EBITDA falls by 50%, FY26 swings to net loss, finance costs jump, shares fall over 5%.
Market Trading Guide: Balrampur Chini, OneSource among 5 stocks for gains up to 11% on Wednesday - The Economic Times
Market Trading Guide: Balrampur Chini, OneSource among 5 stocks for gains up to 11% on WednesdayThe Economic Times
Market Trading Guide: Balrampur Chini, OneSource among 5 stocks for gains up to 11% on Wednesday
OneSource Specialty Pharma receives EU GMP certification for sterile product division
Shares of Onesource Specialty Pharma Ltd ended at ₹1,765.00, down by ₹63.20, or 3.46%, on the BSE.
Onesource Specialty Pharma shares gain after equity worth ₹408 crore changes hands in block deals
The collaboration is to ensure reliable commercial supply from Onesource's USFDA approved flagship site in Bengaluru, the company said.
US drug tariff risk limited for Indian pharma; Sun Pharma exposure in focus: Vishal Manchanda
According to Vishal Manchanda, Pharma Analyst, Systematix Group, potential US action on drug pricing is seen as focused on patented medicines, limiting direct impact on Indian generic manufacturers. Companies with higher exposure to specialty drugs may need to consider pricing agreements to avoid penalties. The expected earnings impact for affected firms remains contained. Sector dynamics continue to favour businesses with lower dependence on US generics, while policy developments and ongoing investigations remain key factors to monitor.
Chennai Petroleum Corporation Ltd leads losers in 'A' group
Kaveri Seed Company Ltd, ITI Ltd, Mangalore Refinery And Petrochemicals Ltd and OneSource Specialty Pharma Ltd are among the other losers in the BSE's 'A' group today, 18 March 2026.
Sun Pharma up 5% in 1 week, nears 52-week high; what's driving this stock?
Sun Pharma is transitioning its US business from low-margin generics to high-value specialty and innovative therapies.
Dipan Mehta prefers pharma, specialty chemicals; stays cautious on IT, exits Info Edge
Dipan Mehta of Elixir Equities prefers pharma and specialty chemicals for medium-term investments, remains cautious on IT amid AI uncertainty, and suggests exiting Info Edge stock.
Newgen Software Technologies Ltd leads losers in 'A' group
Firstsource Solutions Ltd, Latent View Analytics Ltd, OneSource Specialty Pharma Ltd and Le Travenues Technology Ltd are among the other losers in the BSE's 'A' group today, 20 February 2026.
Why the Brooks Steriscience–OneSource deal was called off
OneSource Specialty Pharma said its board decided not to proceed 'in its current form' as it was not in the best interest of stakeholders. Brooks Steriscience echoed a similar stance